Quantitative CT findings may be useful in identifying early, clinically significant airway disease in patients with rheumatoid arthritis.

The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

An expert discussed fam-trastuzumab deruxtecan-nxki for HER2-mutant and -overexpressing non-small cell lung cancer.

The toxin strychnine, the primary component of the traditional Chinese medicine, may act in the STAT3 pathway, investigators ...

Enniskillen author and charity trustee Clare Donohoe recently addressed the Interstitial Lung Disease (ILD) Interdisciplinary Network conference ...

Aumolertinib improved progression-free survival vs placebo in patients with unresectable stage III non–small cell lung cancer ...

Tyr Pharma has a pivotal year ahead with key readouts for Efzofitimod, potentially opening a huge market. Find out why ATYR ...

United Therapeutics’ UTHR third-quarter 2024 earnings of $6.39 per share beat the Zacks Consensus Estimate of $6.18. Earnings ...

Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic ...

Enniskillen author and charity trustee Clare Donohoe recently addressed the Interstitial Lung Disease (ILD) Interdisciplinary ...

The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for the treatment of life-threatening ...